RevBio Receives ISO 13485 Certification for its Quality Management System

2023-05-23 04:28

LOWELL, Mass.--(BUSINESS WIRE)--May 22, 2023--

RevBio, Inc., announced that it has received ISO 13485 certification for its quality management system. Receiving ISO 13485 certification indicates that a company has developed robust policies and procedures for the development and manufacture of regulated medical products.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230522005658/en/

ISO 13485 is designed to be used by organizations involved in the design and production of medical devices and related services. Pictured above, Top (left): ISO 13485 certificate awarded to RevBio; Top (right): Gary Bunnewith, Director of Quality Management and Dave Kosh, Advanced Manufacturing Manager; Bottom (left): D. Grayson Allen (CFO/COO), Brian Hess (CEO), and George Kay (CSO); Bottom (right): RevBio Team working in lab. (Photo: Business Wire)

“Having built my career in quality management over the last 35 years, I have been through over 25 ISO 13485 audits and many FDA audits,” said Gary Bunnewith, RevBio’s Director of Quality. “None have been as exciting as developing a quality management system from the ground up, navigating all the unique regulatory requirements for RevBio’s unique biomaterials platform, and receiving certification as a result of our first audit.” As one of RevBio’s first employees, Gary Bunnewith developed the quality management system and led the audit on behalf of the company. Mr. Bunnewith has an extensive background in the medical device industry, having previously held key quality management positions at Creganna Medical, TE Connectivity Ltd., CR Bard, and Boston Scientific.

The ISO 13485 standard was developed by the International Organization for Standardization (ISO) and is primarily based on the general standard for quality management known as ISO 9001. However, unlike ISO 9001, ISO 13485 was specifically designed for the medical industry and requires a defined approach to risk assessment and the management of each process necessary for the development and realization of regulated medical products. Companies that comply with these quality requirements must prove that they consistently review and validate their product development and manufacturing processes, manage their operations with effective procedures, and maintain records for product traceability.

“Receiving certification to this important quality standard shows that we’re executing on the fundamental company-building initiatives necessary to obtain regulatory approval and ultimately successfully field commercial products,” said Grayson Allen, CFO/COO of RevBio. “This is a major milestone in the development of RevBio and its platform of regenerative bone repair products.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial called TETRANITE®. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's TETRANITE technology is not yet approved for commercial use.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230522005658/en/

CONTACT: Michael Tiedemann

mtiedemann@revbio.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: OTHER MANUFACTURING RESEARCH MEDICAL DEVICES ENGINEERING CLINICAL TRIALS MANUFACTURING BIOTECHNOLOGY HEALTH SCIENCE

SOURCE: RevBio, Inc.

PUB: 05/22/2023 04:18 PM/DISC: 05/22/2023 04:17 PM

http://www.businesswire.com/news/home/20230522005658/en